StockMarketWire.com - Tiziana Life Sciences said it had commenced a clinical trial to test the safety and tolerability of a potential treatment for multiple sclerosis.
The so-called phase one clinical trial would test the Foralumab treatment and be led by Dr. Tanuja Chitnis at the Brigham and Women's Hospital, Harvard Medical School.
Successful demonstration of safety in the study would facilitate immediate evaluation of orally administered Foralumab in a phase two clinical study in patients with progressive multiple sclerosis.
At 8:30am: [LON:TILS] Tiziana Life Sciences Plc share price was +0.5p at 41.5p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.